What is difference between 351(a) vs. 351(k) pathway?
Posted on13 Sep 2017
Comments2
351(a) is the original approval pathway for biologics. It is the pathway for approval of innovator biologics. It is also known as... Read More
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
difference between 351(a) vs. 351(k) pathway
Our Popular Courses
Recent Articles
- Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
- GSK grants exclusive technology license for Ebola vaccines to Sabin Vaccine Institute
- Turalio: USFDA approval of first therapy for rare joint tumor
- Case Study: The Mylan-Upjohn,Pfizer Merger
- Take a Self Competency Test in European Drug Regulatory Affairs
- Strides Pharma received USFDA warning letter for significant violations of CGMP regulations for finished pharmaceuticals
- Case Study : Rituxan – A Brand which Pharma Industry reckon
- In which class should be register the food supplement?
- Cipla’s JV with Jiangsu Acebright Pharma in China
- US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab
- Case Study: Gilead and Galapagos – R&D collaboration
- How data integrity related problems should be addressed in Pharmaceutical and Biopharmaceutical Industry?
- AstraZeneca’s Forxiga gets EMA positive opinion for DECLARE-TIMI 58 cardiovascular outcomes data
- US FDA warning letter: Repackers distributing API for violations of cGMP violation requirements
- Gilead introduces Asia Pacific Rainbow Grants program
- Case Study: EC’s conditional marketing approval to Libtayo for advanced CSCC
- What is Conditional marketing authorisation by European Medicine Agency?
- List of USFDA approved Biosimilar [till date]
- US FDA approves Pfizer’s Biosimilar Zirabev
- What is USFDA Tentative Approval?